Agreement will utilize Imuna’s unique manufacturing capabilities to help address market shortages and deliver innovative, cost-effective and Ready-to-Use premix IV bag products to the U.S. marketplace
Buffalo, NY — Athenex, Inc. announced today a new collaboration between Athenex Pharmaceutical Division (APD) and Imuna Pharm, a.s. (Imuna) to provide specialty injectable products for the United States hospital market. Under the agreement, Imuna will manufacture products for APD in Ready-to-Use premix IV bags. Ready-to-Use premix products allow clinicians to help reduce labor costs, reduce waste, and help reduce medication errors. Athenex and Imuna are excited to offer these products for the United States market that they believe has continued to experience numerous shortages over the years.
Jeffrey Yordon, President of APD, commented, “Our partnership with Imuna is a great step forward for both companies. We believe that APD has secured a partner that has unique capabilities of providing highly sought-after products in a premix Ready-to-Use delivery system, and Imuna has found a partner that has both the reach and commercialization expertise to introduce their product line throughout the U.S. The first focus of the partnership is to concentrate our combined efforts on providing much-needed shortage products to the marketplace. The products are being manufactured in a state-of-the-art facility that is dedicated to delivering high-quality products. We look forward to launching our extensive portfolio of products with Imuna in the U.S. and we’re delighted that many of the products that are anticipated to launch in the U.S. are synergistic with Athenex’s core focus of Oncology and Oncology-related products.”
IMUNA PHARM, a. s. is a pharmaceutical manufacturer with more than 60 years of history based in Šarišské Michalany, Slovakia. Its portfolio consists of infusion solutions, dialysis concentrates, tablets, immunomodulators, vaccines, dietetic preparations, cell implants, allergens and blood derivates. Selling primarily in Europe today, the company distributes and promotes its products through its own sales agencies or via different business partners.
Products of IMUNA PHARM, a.s. are manufactured in accordance with Good Manufacturing Practice (GMP), enabling IMUNA to supply its products to a variety of international markets.
Our high-quality manufacturing, as well as the flexibility and responsiveness of our management team, has allowed IMUNA PHARM, a.s. to become a preferred contract manufacturer for multinational pharmaceutical companies.